Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 5/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4748718 | 0.95 | PKM (0.35) | RAPGEF4PKMKCNH2CYP1A2CYP2C19 | |
| SCHEMBL4105032 | 0.82 | LRRK2 (0.37) | RAPGEF4PKMKCNH2CYP1A2CYP2C19 | |
| SCHEMBL4115341 | 0.81 | RAPGEF4 (0.33) | RAPGEF4PKMKCNH2CYP1A2CYP2C19 | |
| SCHEMBL4751277 | 0.80 | AR (0.40) | — | |
| SCHEMBL4748837 | 0.80 | KDM4E (0.36) | RAPGEF4 | |
| SCHEMBL4730996 | 0.79 | KCNH2 (0.32) | KCNH2JAK2JAK1TYK2JAK3 | |
| SCHEMBL4751023 | 0.79 | KCNH2 (0.37) | RAPGEF4PKMKCNH2CYP1A2CYP2C19 | |
| SCHEMBL4751336 | 0.78 | RAPGEF4 (0.34) | RAPGEF4PKMKCNH2JAK2JAK1 | |
| SCHEMBL4911915 | 0.74 | KCNH2 (0.33) | KCNH2CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL4751578 | 0.74 | KDM4E (0.37) | RAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008135824-A1 | OXYALKYLPYRAZOLE COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2008-11-13 | — | — | WO | disclosed |